Back

The Relationship Between Cannabis Legalization, Suicide and Mental Health Remains Unchanged After Recreational Access

Singer, J. A.; Rich, J. J.; Schemenaur, M.; Capodilupo, R.

2020-09-28 public and global health
10.1101/2020.09.25.20201848 medRxiv
Show abstract

ObjectiveTo standardize the implementation dates of various cannabis liberalization policies and determine whether previous research by Anderson et al. [D.M. Anderson, D.I. Rees, J.J. Sabia, American Journal of Public Health 104, 2369-2376] on medical marijuana access and population-level suicidality is robust to additional years of data and further cannabis liberalization in the form of recreational marijuana access. DesignA state-level longitudinal (panel) analysis. Suicide mortality rates from the National Center for Health Statistics and mental health morbidity rates from the National Survey on Drug Use and Health were employed with the procedures outlined by Anderson et al., using weighted ordinary least squares for three different specifications with various combinations of control variables as a sensitivity analysis to test for robustness. SettingAll 50 states and Washington, DC for the period 1990-2020. ParticipantsUSA population. InterventionsCannabis liberalization policies in the form of recreational and medical access. Primary and Secondary Outcome MeasuresState-level population mental health outcomes in the form of suicide mortality among various age groups for males and females defined by the International Classification of Diseases, Ninth and Tenth Revisions; past-month and -year marijuana use, mental illness, serious mental illness, major depression, and suicidal ideation defined by the Substance Abuse and Mental Health Services Administration. ResultsMedical marijuana access was associated with a 3.3% reduction (95% CI -5.0% to -1.7%) in suicide rates for males, which was mediated by a 5.4% reduction (95% CI -8.0% to -2.7%) among males in the 30 to 39 age group. No other mental health outcomes were consistently affected by cannabis liberalization. ConclusionsAdverse mental health outcomes do not follow cannabis liberalization at the state level, confirming the findings of Anderson et al. In addition, there is evidence that medical marijuana access reduces suicide rates for young-adult males. Strengths and limitations of this studyO_LICannabis liberalization policies, which vary greatly throughout the literature, are explicitly defined and corrected from previous studies. C_LIO_LISAMHSA suppresses state-level geographical information for individual-level responses in the NSDUH, so the analysis relied on population averages for a small number of age groups published in the NSDUH State Prevalence Estimates, which did not allow us to evaluate gender differences for mental health outcomes. C_LIO_LIThe reliability of suicide and NSDUH data to estimate true population rates is highly debated. C_LIO_LIPopulation-level analyses of longitudinal data can be evaluated with multiple accepted methods from the medical literature and it is not clear whether weighted ordinary least squares is the most appropriate approach for this type of analysis. C_LI Funding statementThis research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Competing interests statementReason Foundation is a 501(c)(3) nonprofit organization completely supported by voluntary contributions from individuals, foundations, corporations, and the sale of its publications. Reason Foundations general support includes contributions from marijuana manufacturers, which account for less than one percent of its annual budget. Data sharing statementMost data relevant to the study are publicly available and included as supplementary information. Mortality rates calculated from death counts of less than 10 deaths for any region are suppressed and may require special permissions for access.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Drug and Alcohol Dependence
37 papers in training set
Top 0.1%
19.1%
2
BMJ Open
554 papers in training set
Top 0.7%
19.0%
3
Addiction
25 papers in training set
Top 0.1%
7.3%
4
PLOS ONE
4510 papers in training set
Top 26%
6.5%
50% of probability mass above
5
International Journal of Drug Policy
11 papers in training set
Top 0.1%
6.5%
6
Epidemiology and Psychiatric Sciences
10 papers in training set
Top 0.1%
4.9%
7
JAMA Network Open
127 papers in training set
Top 0.6%
4.4%
8
PLOS Medicine
98 papers in training set
Top 1%
2.8%
9
Psychological Medicine
74 papers in training set
Top 0.8%
1.9%
10
Psychiatry Research
35 papers in training set
Top 0.8%
1.8%
11
Frontiers in Psychiatry
83 papers in training set
Top 2%
1.7%
12
American Journal of Epidemiology
57 papers in training set
Top 0.7%
1.7%
13
The British Journal of Psychiatry
21 papers in training set
Top 0.6%
1.5%
14
Nicotine and Tobacco Research
13 papers in training set
Top 0.1%
1.5%
15
JAMA Psychiatry
13 papers in training set
Top 0.3%
1.2%
16
BMC Public Health
147 papers in training set
Top 5%
0.8%
17
PLOS Global Public Health
293 papers in training set
Top 5%
0.8%
18
JMIR Public Health and Surveillance
45 papers in training set
Top 4%
0.7%
19
Psychiatry and Clinical Neurosciences
11 papers in training set
Top 0.5%
0.7%
20
Journal of Psychiatric Research
28 papers in training set
Top 0.9%
0.7%
21
American Journal of Preventive Medicine
11 papers in training set
Top 0.6%
0.7%
22
Journal of Affective Disorders
81 papers in training set
Top 2%
0.7%
23
American Journal of Psychiatry
20 papers in training set
Top 0.6%
0.5%
24
BMC Medicine
163 papers in training set
Top 9%
0.5%